TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03340532

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: THE INFORMATION + APPEARANCE VIDEO
Description: THE INFORMATION + APPEARANCE VIDEO which will include the full information video, along with an additional embedded video segment emphasizing negative appearance consequences of UV exposure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information SunSmart video
Description: The INFORMATION SunSmart video providing basic information about UV risks, including secondary skin cancer and the benefits of SP, as well as specific SP recommendations and steps to integrate SP as part of routine self-care for the healthy cancer survivor
Study: NCT04233957

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 days of enteric capsules filled with dextrose.
Study: NCT03340532

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sleep hygiene video
Description: Contain information on better sleep hygiene
Study: NCT05016440

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril
Description: 10mg Lisinopril daily for 6-8 weeks postpartum

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lisinopril
Description: 10mg Lisinopril daily for 6-8 weeks postpartum
Study: NCT04124276

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lycium barbarum polysaccharide
Description: Experimental groups take Lycium barbarum polysaccharide (LBP) (300mg/day) for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control group takes placebo (300mg/day) for 6 weeks.
Study: NCT04235114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg 89Zr-DFO-Nimotuzumab
Description: A maximum of 2 mCi (range 1 - 2 mCi) 50 mg of 89Zr-DFO-nimotuzumab will be injected intravenously over a period of at 2 - 3 minutes. Injection will be followed by a normal saline flush of 20-30 mL. PET/CT scan will be done at different time points post infusion.
Study: NCT01376388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719/GW642444 Inhalation Powder
Description: GSK573719/GW642444 inhalation powder inhaled orally once daily for 52 weeks.
Study: NCT04235114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg 89Zr-DFO-Nimotuzumab
Description: A maximum of 2 mCi (range 1 - 2 mCi) 50 mg of 89Zr-DFO-nimotuzumab will be injected intravenously over a period of at 2 - 3 minutes. Injection will be followed by a normal saline flush of 20-30 mL. PET/CT scan will be done at different time points post infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 mg 89Zr-DFO-Nimotuzumab
Description: A maximum of 2 mCi (range 1 - 2 mCi) 1 mg of 89Zr-DFO-nimotuzumab will be injected intravenously over a period of at 2 - 3 minutes. Injection will be followed by a normal saline flush of 20-30 mL. PET/CT scan will be done at different time points post infusion.
Study: NCT01179568

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Description: 16 weeks of medication provided flexibly up to 40 mg/day. Medication will be administered in a double-blind fashion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Description: 16 weeks of medication provided flexibly up to 40 mg/day. Medication will be administered in a double-blind fashion.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Complicated Grief Treatment
Description: Complicated Grief Treatment (CGT) is a targeted psychotherapy for complicated grief. The treatment integrates principles, strategies and techniques from interpersonal psychotherapy, trauma-focused cognitive behavioral treatment and motivational interviewing. Treatment includes 16 sessions provided within 20 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Complicated Grief Treatment
Description: Complicated Grief Treatment (CGT) is a targeted psychotherapy for complicated grief. The treatment integrates principles, strategies and techniques from interpersonal psychotherapy, trauma-focused cognitive behavioral treatment and motivational interviewing. Treatment includes 16 sessions provided within 20 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 16 weeks of daily inactive medication. It will be administered in a double-blind fashion.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 16 weeks of daily inactive medication. It will be administered in a double-blind fashion.
Study: NCT04053114

Intervention type: OTHER
Intervention: DNA and RNA extraction from FFPE or frozen tissue sample
Description: Next generation sequencing (NGS)
Study: NCT00357968

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Prasugrel
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Prasugrel
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Clopidogrel
Description: Administered orally
Study: NCT04140682

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAV+ mode
Description: PAV+ mode by using Puritan-Bennett 840 ventilator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PSV mode
Description: PSV mode by using Puritan-Bennett 840 ventilator
Study: NCT00357968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Clopidogrel
Description: Administered orally
Study: NCT02396615

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: SATIN pineapple
Description: Active juice with added fibre and ginseng

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: SATIN pineapple control
Description: Control products without active ingredients
Study: NCT04753060

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Waxing
Description: Donor sites of patients skin grafts are waxed prior to surgery for donor harvesting.
Study: NCT02821988

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External fetal monitor for Nonstress test
Study: NCT00465205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Description: 500mg oral twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: 500 mg oral twice daily
Study: NCT03308734

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduced-Exertion High-Intensity Interval Training
Description: The 6-week REHIT protocol will involve 3 training sessions a week. Each session will include 10 minutes of unloaded pedalling using a cycle ergometer. Volunteers will be asked to increase to their maximal pedal frequency possible for 1-2 seconds prior to applying a resistance of 5 % of pre-training body weight for the Wingate sprint. The sprints will take place at 2 minutes and at 6 minutes. Sprint duration will be increased from 10 seconds in the first week to 15 seconds in the second and third weeks and finally 20 seconds in the remaining weeks. Patients will receive strong verbal encouragement during the sprints after which the resistance will be removed.
Study: NCT03031678

Intervention type: DEVICE
Group type: OTHER
Intervention: Electric-Acoustic Stimulation (EAS) Cochlear Implant System
Description: Combination of a cochlear implant and a hearing aid
Study: NCT04073589

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARGX-113 with rHuPH20
Description: subcutaneous administration of efgartigimod with recombinant human hyaluronidase PH20 (rHuPH20)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARGX-113 with rHuPH20
Description: subcutaneous administration of efgartigimod with recombinant human hyaluronidase PH20 (rHuPH20)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARGX-113 with rHuPH20
Description: subcutaneous administration of efgartigimod with recombinant human hyaluronidase PH20 (rHuPH20)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARGX-113 with rHuPH20
Description: subcutaneous administration of efgartigimod with recombinant human hyaluronidase PH20 (rHuPH20)
Study: NCT01794884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: 20% N(2)-L-alanyl-L-glutamine 0.4g/kg(2ml/kg) mixed with compound amino acid (10ml/kg).Intravenous injection twice (24 hours、1 hour before operation). Injection rate = 6ml/kg/h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ringer's solution
Description: Ringer's solution 12ml/kg. Intravenous injection twice (24 hours、1 hour before operation). Injection rate = 6ml/kg/h.
Study: NCT01756547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium Citrate
Description: Potassium citrate, oral solution contains Tripotassium citrate monohydrate 20 grams, Citric acid monohydrate 4 grams, distilled water 40 ml, and simple syrup 100ml. The solution contained in a bottle of glass that contains 20 ml of 2 meq/ml of potassium and 2.5 meq/ml of citrate. The dose is 0,3ml/kg/day of the solution until the 38-40 weeks of corrected gestational age or unacceptable toxicity develops.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03726853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator placebo
Description: Comparator placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator placebo
Description: Comparator placebo
Study: NCT01686529

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autoconjunctival grafting
Description: The pterygium head was lifted off the corneal surface by blunt dissection. The pterygium body was dissected from the underlying sclera and thereafter excised. A thorough removal of Tenon's capsule was performed in an area much greater than the pterygium body. Free conjunctival autografting after pteryigum excision was performed as follows: the desired size of the conjunctiva under the upper eyelid was marked and excised. No limbal tissue was included in the graft. The excised tissue was placed on the bare sclera and tightly sutured to the sclera and the limbal area. Finally the autograft edges were sutured to the conjunctiva all around.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autoconjunctival grafting
Description: The pterygium head was lifted off the corneal surface by blunt dissection. The pterygium body was dissected from the underlying sclera and thereafter excised. A thorough removal of Tenon's capsule was performed in an area much greater than the pterygium body. Free conjunctival autografting after pteryigum excision was performed as follows: the desired size of the conjunctiva under the upper eyelid was marked and excised. No limbal tissue was included in the graft. The excised tissue was placed on the bare sclera and tightly sutured to the sclera and the limbal area. Finally the autograft edges were sutured to the conjunctiva all around.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autoconjunctival grafting
Description: The pterygium head was lifted off the corneal surface by blunt dissection. The pterygium body was dissected from the underlying sclera and thereafter excised. A thorough removal of Tenon's capsule was performed in an area much greater than the pterygium body. Free conjunctival autografting after pteryigum excision was performed as follows: the desired size of the conjunctiva under the upper eyelid was marked and excised. No limbal tissue was included in the graft. The excised tissue was placed on the bare sclera and tightly sutured to the sclera and the limbal area. Finally the autograft edges were sutured to the conjunctiva all around.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subconjuntival bevacizumab injection
Description: The subconjunctival injection of bevacizumab was applied adjacent to the site of pterygium separation inside the healthy conjunctiva. The half of the dose (1.25 mg/0.05ml) was applied in the nasal inferior quadrant, and the other half of the dose was applied in the nasal superior quadrant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subconjuntival bevacizumab injection
Description: The subconjunctival injection of bevacizumab was applied adjacent to the site of pterygium separation inside the healthy conjunctiva. The half of the dose (1.25 mg/0.05ml) was applied in the nasal inferior quadrant, and the other half of the dose was applied in the nasal superior quadrant.
Study: NCT02956421

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RABIPUR®
Description: Biological rabies vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PIKA rabies vaccine
Description: Biological rabies vaccine
Study: NCT02821988

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonography for Biophysical profile
Study: NCT00817037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitaxsentan
Description: Sitaxsentan 100mg once daily oral dosing for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Description: Nifedipine 30mg once daily oral dosing for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet once daily oral dosing for 6 weeks
Study: NCT01325584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omegaven
Description: initial dose of 0.1 g/kg body weight (1ml/kg) and increased to 0.2 g/kg body weight (2ml/kg) on day 2 or 3 of treatment. The infusion rate will not exceed 0.5mL Omegaven/kg body weight/hr (corresponding to 0.05g fish oil/kg/hr). Patients will receive the initial infusion of PN containing Omegaven at Midwestern Regional Medical Center (MRMC) in the infusion center to observe for adverse reactions. Patients will continue to receive infusions at MRMC for the first 2 to 3 days of dosing. After tolerance is established, patients will receive treatment at home. All study patients will have a Screening Visit; Day 1, Day 2 and Day 3 visits; and weekly visits for one month.
Study: NCT03952104

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training
Description: Strength training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training
Description: Strength training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training
Description: Strength training
Study: NCT06177587

Intervention type: OTHER
Intervention: Assesment of biomarkers in acute coronary syndromes
Description: Collection of 20ml of blood from peripheral vein.

Intervention type: OTHER
Intervention: Assesment of biomarkers in acute coronary syndromes
Description: Collection of 20ml of blood from peripheral vein.
Study: NCT01343498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235
Description: BEZ235 will be given on a dose-escalation design, beginning at 200 mg BID (SDS sachet) in 3 patients and progressing to 400 mg, 600 mg, and 800 mg respectively based on tolerability.
Study: NCT01305902

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: contingency management
Description: Participants assigned to the experimental group will earn chances to win prizes if they have walked the recommended number of steps.
Study: NCT03726853

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator placebo
Description: Comparator placebo
Study: NCT04383223

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iTransition
Description: Is a mobile website application (app), and it can be used on a range of devices (computer, tablet, smartphone) and operating systems (iOS, Android, Windows). Features of iTransition will include, but are not limited to: medication reminders, calendar tracking of appointments, direct messaging between youth and providers, and privacy password lock.
Study: NCT05541952

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: Revaccination with BCG, using the immunobiological used in the Brazilian public health network, strain Russia.
Study: NCT00929799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human Growth Hormone (Genotropin® )
Description: Once daily by subcutaneous injection using a Genotropin pen in the abdomen at 22:00 h. Maximal GH dose of 0.003 mg/kg/day.
Study: NCT04449575

Intervention type: OTHER
Intervention: eSwabs
Description: from skin

Intervention type: OTHER
Intervention: eSwabs
Description: from skin
Study: NCT02684916

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chiropractic treatment
Description: The child receives chiropractic manipulation treatment in the neck and in the spine and pelvis according to individual needs. They also receive a written list of general advice regarding lifestyle and habits.~The parents and the child are unaware of group allocation.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-therapeutic placebo treatment: a broad non-specific contact outside the spinal column is taken on subject's scapula and gluteal region lying in a side posture position, on the scapulae in a prone position and on trapezius muscles in a sitting position. In those positions the chiropractor pushes in a non-intentional and non- therapeutic directional line with a low-amplitude, low velocity push maneuver. All contacts are performed without soft tissue pre-tension and gentle contact, to insure that no joint cavitation occurs. To obtain a noise that many people associate with a chiropractic spinal adjustment, a de-activated Activator Instrument is used on the arm of the chiropractor to give a click-sound. General advice on lifestyle and habits is handed out to the placebo group as well.
Study: NCT02704715

Intervention type: PROCEDURE
Group type: OTHER
Intervention: general anesthesia,orbital operation
Description: to evaluate the pain under general anesthesia
Study: NCT03641924

Intervention type: BEHAVIORAL
Intervention: Cognitive Processing Therapy
Description: Cognitive Processing Therapy is an evidence-based psychotherapy for PTSD.
Study: NCT02881437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IgHy10
Description: Sub Cutaneous IgHy10 administration
Study: NCT00403234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine transdermal patches 10 mcg/h and 20 mcg/h (total of 30 mcg/h) applied for 7-day wear.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo BTDS
Description: Placebo to match BTDS transdermal 10 and 20 patches applied for 7-day wear.
Study: NCT00784498

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine/Midazolam
Description: Intravenous bolus of midazolam 0.1mg/kg in titrated dose of 1 mg/min until spontaneous eye closure or up to 5mg (whichever comes first) followed by ketamine 0.5-1mg/kg (up to 100mg) in titrated dose of 10mg/30 seconds, to achieve the desired level of sedation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Intravenous bolus of propofol 0.5-1mg/kg in titrated dose of 10mg/30seconds (up to 100mg) to achieve the desired level of sedation
Study: NCT01897454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study: NCT01361152

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: anatomic modular fixed-bearing
Description: anatomic modular (AMK; DePuy) fixed-bearing prosthesis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low contact stress rotating platform mobile-bearing
Description: low contact stress rotating platform (LCS RP; DePuy) mobile-bearing prosthesis
Study: NCT01542125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Lidocaine
Description: 4% Liposomal Lidocaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tubes were visually identical to the Liposomal Lidocaine tubes.
Study: NCT01372267

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation for substance abuse
Description: This active control provides detailed educational information about substance use and chronic pain to those enrolled.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for pain in Substance abuse
Description: The therapeutic intervention group is designed to provide beneficial coping strategies that are helpful in dealing with both substance use and pain.
Study: NCT02176499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan, low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan, high dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT04250883

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low intra-abdominal pressure
Description: 8 mmHg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade (NMB)
Description: Deep NMB (PTC1-2)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard intra-abdominal pressure
Description: 14 mmHg

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate neuromuscular blockade (NMB)
Description: Moderate NMB (TOF 1-2)
Study: NCT03464305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid
Description: Patients treated with acetylsalicylic acid 80 mg once daily for 5 years. Patients will be stratified according to the admission of adjuvant chemotherapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients treated with placebo. Patients will be stratified according to the admission of adjuvant chemotherapy.
Study: NCT00982137

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated Japanese encephalitis virus; Yellow fever virus
Description: ChimeriVax™-JE, 0.5 mL, Subcutaneous on Day 0; STAMARIL®, 0.5 mL, Subcutaneous on Day 30.